SyntekaBio, Inc. announced that it expects to receive KRW 25 billion in funding from Shinhan Financial Investment Co., Ltd., Saneun Capital Co., Ltd., Best Investment & Securities Co., Ltd., IBK Capital Corporation, KDB Capital Corp., Shinhan Investment Corp., Investment Arm and other investors
November 24, 2021
Share
SyntekaBio, Inc. announced that it will issue series 1 non-guaranteed private convertible bonds with bearer type interest part for gross proceeds of KRW 25,000,000,000 and series 4 unregistered coupon nonguaranteed private convertible bond for gross proceeds of KRW 25,000,000,000 and aggregate gross proceeds of KRW 50,000,000,000 on November 25, 2021. The bonds will be issued at par. The transaction included participation from Tigris Fund No. 43 for KRW 5,000,000,000, Time Folio KOSDAQ Venture for KRW 2,000,000,000, , Fine Value Mezzanine Plus Specialized Investment Criminal Securities Investment Trust for KRW 1,000,000,000, Fine Value IPO Plus Specialized Investment Criminal Securities Investment Trust for KRW 1,000,000,000, Best Investment & Securities Co., Ltd. for KRW 1,000,000,000, GBA The banks 2 general private equity trust KRW 1,000,000,000, GBA Coven-V General Private Equity Trust KRW 1,000,000,000, GBA Saber-G General Private Equity Trust for KRW 100,000,000, GBA Saber-V General Private Equity Trust for KRW 200,000,000, Fortress-A General Private Equity Trust for KRW 2,700,000,000, IBK Capital Corporation for KRW 2,000,000,000, DS K-01 KOSDAQ Venture Specialized Investment Private Equity Trust for KRW 1,000,000,000 and DS K-02 KOSDAQ Venture Specialized Investment Type Private Equity Trust for KRW 2,000,000,000 each in series 1 and series 4 bonds, Shinhan Financial Investment Co., Ltd. for KRW 1,000,000,000, Saneun Capital Co., Ltd. for KRW 3,000,000,000, KDB Capital Corp. for KRW 3,000,000,000 and Shinhan Investment Corp., Investment Arm for KRW 1,000,000,000. The bonds are zero coupon bonds and have maturity rate of 2% per annum. The series 1 and series 4 bonds will mature on November 30, 2026. The series 1 and series 4 bonds are convertible into 1,857,493 common shares at a fixed conversion price of KRW 13,459 per share from November 30, 2022 to October 30, 2026. The date of subscription is November 26, 2021 and expected date of payment is November 30, 2021. The transaction is approved by the board of directors of the company. The securities are subject to a hold period of one year from the date of issue.
Syntekabio,Inc. is a Korea-based company principally engaged in the provision of database and software. The Company develops and sells software such as personal algorithm dielectric map platform (PMAP) using artificial intelligence (AI) technology, provides clinical trial modeling and genome analysis services through big data. The analysis results are used to diagnose genetic diseases, select biomarker treatments and predict disease risk. In addition, the Company develops AI drug development technology, provides research services for candidate substances of immuno-cancer drugs.
SyntekaBio, Inc. announced that it expects to receive KRW 25 billion in funding from Shinhan Financial Investment Co., Ltd., Saneun Capital Co., Ltd., Best Investment & Securities Co., Ltd., IBK Capital Corporation, KDB Capital Corp., Shinhan Investment Corp., Investment Arm and other investors